Land: Kanada
Språk: engelska
Källa: Health Canada
ACETYLSALICYLIC ACID
VITA HEALTH PRODUCTS INC
B01AC06
ACETYLSALICYLIC ACID
81MG
TABLET (ENTERIC-COATED)
ACETYLSALICYLIC ACID 81MG
ORAL
1000
OTC
SALICYLATES
Active ingredient group (AIG) number: 0101169013; AHFS:
APPROVED
2014-07-30
Jamp - ASA 81 mg EC Page 1 of 46 PRODUCT MONOGRAPH JAMP - ASA 81 MG EC Acetylsalicylic Acid Delayed Release Tablets 81 mg USP Platelet aggregation inhibitor Vita Health Products Inc. 150 Beghin Avenue Winnipeg, MB Canada R2J 3W2 Control Number: 264031 Date of Preparation: February 3, 2011 Date of Revision : September 1, 2022 Jamp - ASA 81 mg EC Page 2 of 46 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................... 3 SUMMARY PRODUCT INFORMATION .............................................................................. 3 INDICATIONS AND CLINICAL USE ................................................................................... 3 CONTRAINDICATIONS........................................................................................................ 4 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ........................................................................................................ 7 DRUG INTERACTIONS ........................................................................................................ 7 DOSAGE AND ADMINISTRATION ..................................................................................... 9 OVERDOSAGE.....................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ....................................................................11 STORAGE AND STABILITY ...............................................................................................13 DOSAGE FORMS, COMPOSITION AND PACKAGING......................................................13 PART II: SCIENTIFIC INFORMATION ......................................................................... 14 PHARMACEUTICAL INFORMATION ................................................................................14 CLINICAL TRIALS................................................................ Läs hela dokumentet